0041U Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM

Name of the Procedure:

Borrelia burgdorferi, Antibody Detection of 5 Recombinant Protein Groups, by Immunoblot, IgM (Common Name: Lyme Disease Test, Borrelia IgM Western Blot)

Summary

This procedure detects specific antibodies (IgM) against Borrelia burgdorferi, the bacteria responsible for Lyme disease. It uses an immunoblot technique to identify reactions to five different recombinant protein groups associated with this bacteria.

Purpose

This test primarily diagnoses early-stage Lyme disease, detecting the body's immune response to the infection. Outcomes aim for early detection, allowing timely treatment which can effectively prevent complications.

Indications

• Symptoms suggestive of early Lyme disease, such as erythema migrans (rash), flu-like symptoms, joint pain.
• Patients with potential exposure to tick bites in endemic areas.
• Confirmatory testing following an initial positive or equivocal ELISA test for Lyme disease.

Preparation

• No specific preparations such as fasting are required.
• Patients might be advised to avoid certain medications that can interfere with immune responses.
• Usually, a prior ELISA test is conducted to justify the necessity for the immunoblot.

Procedure Description

1. A blood sample is drawn from the patient.
2. The sample is processed to isolate serum.
3. The serum is exposed to a gel containing recombinant Borrelia protein groups.
4. Any antibodies present will bind to the proteins and be visualized using a chemiluminescent substrate.
5. The results are analyzed to determine the presence of IgM antibodies indicative of Borrelia burgdorferi infection.

Duration

The blood draw takes a few minutes, but processing and analysis can take several hours to a few days depending on the laboratory's workflow.

Setting

This procedure is performed in a clinical laboratory.

Personnel

• Phlebotomist for blood draw
• Laboratory technician or medical technologist for test processing
• Clinical pathologist for result interpretation

Risks and Complications

• Minimal risk from blood draw (e.g., slight pain, bruising, or risk of infection at the puncture site).
• Rarely, false positives or negatives leading to misdiagnosis.

Benefits

• Early and accurate detection of Lyme disease.
• Can confirm Lyme disease where other tests may be ambiguous.
• Leading to appropriate and timely treatment, reducing the risk of chronic complications.

Recovery

• No specific recovery needed post-blood draw.
• Normal daily activities can generally be resumed immediately.
• Follow-up with a healthcare provider to discuss results and potential treatment.

Alternatives

• Enzyme-linked Immunosorbent Assay (ELISA) for initial Lyme disease screening.
• Direct detection methods like PCR for Borrelia DNA in certain cases.
• Clinical diagnosis based on symptoms and history without confirmatory serological testing.

Patient Experience

• Slight discomfort during the blood draw similar to any standard blood test.
• Anxiety while waiting for results.
• No pain or sedation required.
• Comfort measures: patients are encouraged to stay relaxed and hydrated before the sample collection.